𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Tolerability of switching from donepezil to memantine treatment in patients with moderate to severe Alzheimer's disease

✍ Scribed by Gunhild Waldemar; Maritta Hyvärinen; Mette Krog Josiassen; Alex Kørner; Heikki Lehto; Peter Wetterberg

Publisher
John Wiley and Sons
Year
2008
Tongue
English
Weight
44 KB
Volume
23
Category
Article
ISSN
0885-6230

No coin nor oath required. For personal study only.

✦ Synopsis

This study investigates the tolerability, safety and efficacy of abrupt or stepwise switching from donepezil to memantine treatment in patients with moderate-to-severe Alzheimer's disease (AD). Outpatients (Table 1), !50 years, with dementia of the Alzheimer's type (DSM-IV-TR), MMSE 18 and receiving donepezil !6 months preceding screening, were eligible for the study if the donepezil treatment was failing as judged by the clinician. Failing efficacy of donepezil was supported by an MMSE assessment by the clinician, worsening of behaviour and/or ADL functions by caregiver report. Investigators screened patients using a physical examination, medical history, ECG and clinical laboratory tests in order to ascertain that they were otherwise healthy and eligible for memantine treatment.

All patients received 10 mg/day donepezil for a 1-2 week screening period. At Week 0, patients were randomised (1:1) to either placebo (abrupt) or 5 mg/ day donepezil (stepwise discontinuation) for 2 weeks.

📜 SIMILAR VOLUMES

Improvement in behavioural symptoms in p
Improvement in behavioural symptoms in patients with moderate to severe Alzheimer's disease by memantine: a pooled data analysis
✍ S. Gauthier; H. Loft; J. Cummings 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 118 KB 👁 1 views

## Abstract ## Introduction Behavioural disturbances are a common and distressing aspect of Alzheimer's disease (AD). This pooled analysis evaluated the specific benefits of memantine on behavioural disturbances in patients with moderate to severe AD. ## Methods Data were pooled from six 24/28‐w

Safety and tolerability of once-daily ve
Safety and tolerability of once-daily versus twice-daily memantine: a randomised, double-blind study in moderate to severe Alzheimer's disease
✍ Roy W. Jones; Antony Bayer; Fraser Inglis; Andrew Barker; Ravinder Phul 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 97 KB 👁 1 views

## Abstract ## Objective To assess the safety and tolerability of three different dosing schedules of memantine in patients with moderate to severe Alzheimer's disease (AD). ## Method This 12‐week, randomised, double‐blind study, investigated three dosing schedules of memantine: OD1 (20 mg once

Donepezil for the symptomatic treatment
Donepezil for the symptomatic treatment of patients with mild to moderate Alzheimer's disease: a meta-analysis of individual patient data from randomised controlled trials
✍ Anne Whitehead; Carlos Perdomo; Raymond D. Pratt; Jacqueline Birks; Gordon K. Wi 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 105 KB 👁 3 views

## Abstract ## Background The objective was to evaluate the efficacy and tolerability of donepezil (5 and 10 mg/day) compared with placebo in alleviating manifestations of mild to moderate Alzheimer's disease (AD). ## Method A systematic review of individual patient data from Phase II and III do

A multinational, randomised, 12-week stu
A multinational, randomised, 12-week study comparing the effects of donepezil and galantamine in patients with mild to moderate Alzheimer's disease
✍ Roy W. Jones; Hilkka Soininen; Klaus Hager; Dag Aarsland; Peter Passmore; Anita 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 180 KB 👁 2 views

## Abstract ## Objectives To compare directly, in the same patient cohort, the ease of use and tolerability of donepezil and galantamine in the treatment of Alzheimer's disease (AD), and investigate the effects of both treatments on cognition and activities of daily living (ADL). ## Methods Pati

Effects of memantine on cognition in pat
Effects of memantine on cognition in patients with moderate to severe Alzheimer's disease: post-hoc analyses of ADAS-cog and SIB total and single-item scores from six randomized, double-blind, placebo-controlled studies
✍ Patrizia Mecocci; Anna Bladström; Karina Stender 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 129 KB 👁 2 views

## Abstract ## Objectives The post‐hoc analyses reported here evaluate the specific effects of memantine treatment on ADAS‐cog single‐items or SIB subscales for patients with moderate to severe AD. ## Methods Data from six multicentre, randomised, placebo‐controlled, parallel‐group, double‐blind